Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Radiosensitization effect of Huaier on breast cancer cells.

Ding X, Yang Q, Kong X, Haffty BG, Gao S, Moran MS.

Oncol Rep. 2016 May;35(5):2843-50. doi: 10.3892/or.2016.4630. Epub 2016 Feb 23.

PMID:
26935024
2.

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ.

Clin Breast Cancer. 2016 Apr;16(2):113-122.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1.

3.

Breast Cancer, Version 1.2016.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.

PMID:
26656517
4.

Radiation therapy in the locoregional treatment of triple-negative breast cancer.

Moran MS.

Lancet Oncol. 2015 Mar;16(3):e113-22. doi: 10.1016/S1470-2045(14)71104-0. Review.

PMID:
25752562
5.

Perspectives in breast cancer treatment: APBI and breast-conserving surgery. In reply to Morgan and Vaidya.

Truong PT, Smith SL, Moran MS.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):967-8. doi: 10.1016/j.ijrobp.2014.07.047. Epub 2014 Oct 18. No abstract available.

PMID:
25585789
6.

Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated partial-breast irradiation.

Wobb JL, Chen PY, Shah C, Moran MS, Shaitelman SF, Vicini FA, Mbah AK, Lyden M, Beitsch P.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):312-8. doi: 10.1016/j.ijrobp.2014.09.029. Epub 2014 Nov 11.

PMID:
25446607
7.

The Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer: Perspectives for Pathologists.

Schnitt SJ, Moran MS, Houssami N, Morrow M.

Arch Pathol Lab Med. 2015 May;139(5):575-7. doi: 10.5858/arpa.2014-0384-ED. Epub 2014 Aug 25. No abstract available.

PMID:
25153620
8.

In reply to Dixon and Thomas.

Moran MS, Houssami N, Schnitt SJ, Morrow M.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1139-41. doi: 10.1016/j.ijrobp.2014.04.032. Epub 2014 Jul 8. No abstract available. Erratum in: Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1262. Schnitt, Stewart J [corrected to Schnitt, Stuart J].

PMID:
25035221
9.

Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?

Moran MS.

Am Soc Clin Oncol Educ Book. 2014:e32-6. doi: 10.14694/EdBook_AM.2014.34.e32. Review.

10.

Analysis of coronary artery dosimetry in the 3-dimensional era: Implications for organ-at-risk segmentation and dose tolerances in left-sided tangential breast radiation.

Evans SB, Panigrahi B, Northrup V, Patterson J, Baldwin DE, Higgins SA, Moran MS.

Pract Radiat Oncol. 2013 Apr-Jun;3(2):e55-60. doi: 10.1016/j.prro.2012.06.007. Epub 2012 Jul 24.

PMID:
24674321
11.

Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):553-64. doi: 10.1016/j.ijrobp.2013.11.012.

12.

Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M; Society of Surgical Oncology; American Society for Radiation Oncology.

J Clin Oncol. 2014 May 10;32(14):1507-15. doi: 10.1200/JCO.2013.53.3935. Epub 2014 Feb 10.

13.

Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M.

Ann Surg Oncol. 2014 Mar;21(3):704-16. doi: 10.1245/s10434-014-3481-4. Epub 2014 Feb 10.

PMID:
24515565
14.

Prokaryotic Super Program Advisory Committee DOE Joint Genome Institute, Walnut Creek, CA, March 27, 2013.

Garrity GM, Banfield J, Eisen J, van der Lelie N, McMahon T, Rusch D, Delong E, Moran MA, Currie C, Furhman J, Hallam S, Hugenholtz P, Moran N, Nelson K, Roberts R, Stepanauskas R.

Stand Genomic Sci. 2013 Jul 30;8(3):561-70. doi: 10.4056/sigs.4638348. eCollection 2013 Jul 30.

15.

Should low-risk patients be treated with three-dimensional conformal radiation therapy-accelerated partial-breast irradiation in an off-protocol setting?

Moran MS.

J Clin Oncol. 2013 Nov 10;31(32):4032-7. doi: 10.1200/JCO.2013.51.1642. Epub 2013 Sep 30. Review. No abstract available.

PMID:
24081936
16.

Is Ki-67 expression prognostic for local relapse in early-stage breast cancer patients treated with breast conservation therapy (BCT)?

Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):344-8. doi: 10.1016/j.ijrobp.2013.05.052. Epub 2013 Aug 1.

PMID:
23910708
17.

What currently defines a breast center? Initial data from the national accreditation program for breast centers.

Moran MS, Kaufman C, Burgin C, Swain S, Granville T, Winchester DP.

J Oncol Pract. 2013 Mar;9(2):e62-70. doi: 10.1200/JOP.2012.000636.

18.

Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?

Bai HX, Motwani SB, Higgins SA, Haffty BG, Wilson LD, Lannin DR, Evans SB, Moran MS.

Int J Clin Oncol. 2014;19(3):460-6. doi: 10.1007/s10147-013-0575-0. Epub 2013 Jun 19.

PMID:
23780727
19.

Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?

Jones T, Neboori H, Wu H, Yang Q, Haffty BG, Evans S, Higgins S, Moran MS.

Ann Surg Oncol. 2013 Sep;20(9):2866-72. doi: 10.1245/s10434-013-2994-6. Epub 2013 May 10.

PMID:
23661183
20.

Testin is a tumor suppressor and prognostic marker in breast cancer.

Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG, Yang Q.

Cancer Sci. 2012 Dec;103(12):2092-101. doi: 10.1111/cas.12020. Epub 2012 Oct 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk